← All trials
NCT04634409
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Mar 15, 2021
- First posted
- Nov 18, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 700
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eli LillyLead sponsor
- Eli LillyStudy director
- Shanghai Junshi Bioscience Co.,Ltd.Collaborator
- AbCellera Biologics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.